{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T16:47:31Z","timestamp":1780332451865,"version":"3.54.1"},"reference-count":92,"publisher":"Elsevier BV","issue":"30","license":[{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000060","name":"Vaccine Research Center, National Institute of Allergy and Infectious Diseases, NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1016\/j.vaccine.2016.04.083","type":"journal-article","created":{"date-parts":[[2016,5,13]],"date-time":"2016-05-13T20:56:38Z","timestamp":1463172998000},"page":"3535-3541","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":84,"title":["Vaccines against respiratory syncytial virus: The time has finally come"],"prefix":"10.1016","volume":"34","author":[{"given":"Barney S.","family":"Graham","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.vaccine.2016.04.083_bib0465","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1056\/NEJMoa0804877","article-title":"The burden of respiratory syncytial virus infection in young children","volume":"360","author":"Hall","year":"2009","journal-title":"N Engl J Med"},{"issue":"9859","key":"10.1016\/j.vaccine.2016.04.083_bib0470","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1016\/S0140-6736(12)61728-0","article-title":"Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010","volume":"380","author":"Lozano","year":"2012","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.vaccine.2016.04.083_bib0475","first-page":"543","article-title":"Risk of primary infection and reinfection with respiratory syncytial virus","volume":"140","author":"Glezen","year":"1986","journal-title":"Am J Dis Child"},{"issue":"6","key":"10.1016\/j.vaccine.2016.04.083_bib0480","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1086\/322657","article-title":"Respiratory syncytial virus infections in previously healthy working adults","volume":"33","author":"Hall","year":"2001","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.vaccine.2016.04.083_bib0485","doi-asserted-by":"crossref","first-page":"203","DOI":"10.7326\/0003-4819-88-2-203","article-title":"Respiratory syncytial virus infection in adults: clinical, virologic, and serial pulmonary function studies","volume":"88","author":"Hall","year":"1978","journal-title":"Ann Intern Med"},{"issue":"5","key":"10.1016\/j.vaccine.2016.04.083_bib0490","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1097\/00005792-198909000-00002","article-title":"Respiratory syncytial virus-induced acute lung injury in adult patients with bone marrow transplants: a clinical approach and review of the literature","volume":"68","author":"Hertz","year":"1989","journal-title":"Medicine (Baltimore)"},{"issue":"2","key":"10.1016\/j.vaccine.2016.04.083_bib0495","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1086\/421779","article-title":"Quantitative effects of palivizumab and donor-derived T cells on chronic respiratory syncytial virus infection, lung disease, and fusion glycoprotein amino acid sequences in a patient before and after bone marrow transplantation","volume":"39","author":"El Saleeby","year":"2004","journal-title":"Clin Infect Dis"},{"issue":"17","key":"10.1016\/j.vaccine.2016.04.083_bib0500","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1056\/NEJMoa043951","article-title":"Respiratory syncytial virus infection in elderly and high-risk adults","volume":"352","author":"Falsey","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2016.04.083_bib0505","first-page":"39","article-title":"Clinical and epidemiologic features of respiratory syncytial virus","volume":"372","author":"Hall","year":"2013","journal-title":"Curr Top Microbiol Immunol"},{"issue":"6","key":"10.1016\/j.vaccine.2016.04.083_bib0510","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1067\/mpd.2000.110531","article-title":"Rates of hospitalization for respiratory syncytial virus infection among children in medicaid","volume":"137","author":"Boyce","year":"2000","journal-title":"J Pediatr"},{"issue":"10","key":"10.1016\/j.vaccine.2016.04.083_bib0515","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1093\/cid\/cis211","article-title":"Hospitalizations associated with influenza and respiratory syncytial virus in the United States, 1993\u20132008","volume":"54","author":"Zhou","year":"2012","journal-title":"Clin Infect Dis"},{"issue":"2 Suppl.","key":"10.1016\/j.vaccine.2016.04.083_bib0520","doi-asserted-by":"crossref","first-page":"S76","DOI":"10.1097\/01.inf.0000053889.39392.a7","article-title":"Respiratory syncytial virus bronchiolitis and the pathogenesis of childhood asthma","volume":"22","author":"Martinez","year":"2003","journal-title":"Pediatr Infect Dis J"},{"issue":"9178","key":"10.1016\/j.vaccine.2016.04.083_bib0525","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S0140-6736(98)10321-5","article-title":"Respiratory syncytial virus in early life and risk of wheeze and allergy by age 13 years","volume":"354","author":"Stein","year":"1999","journal-title":"Lancet"},{"issue":"19","key":"10.1016\/j.vaccine.2016.04.083_bib0530","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1056\/NEJMoa1211917","article-title":"Respiratory syncytial virus and recurrent wheeze in healthy preterm infants","volume":"368","author":"Blanken","year":"2013","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.vaccine.2016.04.083_bib0535","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1128\/CMR.00017-08","article-title":"Human genetic factors and respiratory syncytial virus disease severity","volume":"21","author":"Miyairi","year":"2008","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.vaccine.2016.04.083_bib0540","first-page":"121","article-title":"Human genetics and respiratory syncytial virus disease: current findings and future approaches","volume":"372","author":"Choi","year":"2013","journal-title":"Curr Top Microbiol Immunol"},{"issue":"1","key":"10.1016\/j.vaccine.2016.04.083_bib0545","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/modpathol.3800725","article-title":"The histopathology of fatal untreated human respiratory syncytial virus infection","volume":"20","author":"Johnson","year":"2007","journal-title":"Modern Pathol: Off J US Can Acad Pathol Inc"},{"issue":"8","key":"10.1016\/j.vaccine.2016.04.083_bib0550","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1056\/NEJM197602192940803","article-title":"Respiratory syncytial virus infections within families","volume":"294","author":"Hall","year":"1976","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.vaccine.2016.04.083_bib0555","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1093\/infdis\/jit828","article-title":"The source of respiratory syncytial virus infection in infants: a household cohort study in rural Kenya","volume":"209","author":"Munywoki","year":"2014","journal-title":"J Infect Dis"},{"issue":"10","key":"10.1016\/j.vaccine.2016.04.083_bib0560","doi-asserted-by":"crossref","first-page":"e1001527","DOI":"10.1371\/journal.pmed.1001527","article-title":"Assessing optimal target populations for influenza vaccination programmes: an evidence synthesis and modelling study","volume":"10","author":"Baguelin","year":"2013","journal-title":"PLoS Med"},{"issue":"2","key":"10.1016\/j.vaccine.2016.04.083_bib0565","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.vaccine.2015.05.093","article-title":"WHO consultation on Respiratory Syncytial Virus Vaccine Development Report from a World Health Organization Meeting held on 23\u201324 March 2015","volume":"34","author":"Modjarrad","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.04.083_bib0570","first-page":"3","article-title":"Respiratory syncytial virus: virology, reverse genetics, and pathogenesis of disease","volume":"372","author":"Collins","year":"2013","journal-title":"Curr Top Microbiol Immunol"},{"issue":"9","key":"10.1016\/j.vaccine.2016.04.083_bib0575","doi-asserted-by":"crossref","first-page":"5326","DOI":"10.1128\/JVI.79.9.5326-5336.2005","article-title":"RhoA signaling is required for respiratory syncytial virus-induced syncytium formation and filamentous virion morphology","volume":"79","author":"Gower","year":"2005","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2016.04.083_bib0580","first-page":"83","article-title":"Structure and function of respiratory syncytial virus surface glycoproteins","volume":"372","author":"McLellan","year":"2013","journal-title":"Curr Top Microbiol Immunol"},{"issue":"309","key":"10.1016\/j.vaccine.2016.04.083_bib0585","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aac4241","article-title":"Prefusion F-specific antibodies determine the magnitude of RSV neutralizing activity in human sera","volume":"7","author":"Ngwuta","year":"2015","journal-title":"Sci Transl Med"},{"issue":"8","key":"10.1016\/j.vaccine.2016.04.083_bib0590","doi-asserted-by":"crossref","first-page":"3089","DOI":"10.1073\/pnas.1115941109","article-title":"Neutralizing antibodies against the preactive form of respiratory syncytial virus fusion protein offer unique possibilities for clinical intervention","volume":"109","author":"Magro","year":"2012","journal-title":"Proc Natl Acad Sci USA"},{"issue":"7","key":"10.1016\/j.vaccine.2016.04.083_bib0595","doi-asserted-by":"crossref","first-page":"e1005035","DOI":"10.1371\/journal.ppat.1005035","article-title":"Characterization of a prefusion-specific antibody that recognizes a quaternary, cleavage-dependent epitope on the RSV fusion glycoprotein","volume":"11","author":"Gilman","year":"2015","journal-title":"PLOS Pathog"},{"key":"10.1016\/j.vaccine.2016.04.083_bib0600","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.coviro.2015.03.002","article-title":"Neutralizing epitopes on the respiratory syncytial virus fusion glycoprotein","volume":"11","author":"McLellan","year":"2015","journal-title":"Curr Opin Virol"},{"issue":"23","key":"10.1016\/j.vaccine.2016.04.083_bib0605","doi-asserted-by":"crossref","first-page":"12236","DOI":"10.1128\/JVI.01579-10","article-title":"Structure of a major antigenic site on the respiratory syncytial virus fusion glycoprotein in complex with neutralizing antibody 101F","volume":"84","author":"McLellan","year":"2010","journal-title":"J Virol"},{"issue":"2","key":"10.1016\/j.vaccine.2016.04.083_bib0610","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/nsmb.1723","article-title":"Structural basis of respiratory syncytial virus neutralization by motavizumab","volume":"17","author":"McLellan","year":"2010","journal-title":"Nat Struct Mol Biol"},{"issue":"6136","key":"10.1016\/j.vaccine.2016.04.083_bib0615","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1126\/science.1234914","article-title":"Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody","volume":"340","author":"McLellan","year":"2013","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.vaccine.2016.04.083_bib0620","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1128\/JVI.63.2.925-932.1989","article-title":"Marked differences in the antigenic structure of human respiratory syncytial virus F and G glycoproteins","volume":"63","author":"Garcia-Barreno","year":"1989","journal-title":"J Virol"},{"issue":"7","key":"10.1016\/j.vaccine.2016.04.083_bib0625","doi-asserted-by":"crossref","first-page":"2941","DOI":"10.1128\/JVI.63.7.2941-2950.1989","article-title":"Neutralization epitopes of the F glycoprotein of respiratory syncytial virus: effect of mutation upon fusion function","volume":"63","author":"Beeler","year":"1989","journal-title":"J Virol"},{"issue":"Pt 10","key":"10.1016\/j.vaccine.2016.04.083_bib0630","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1099\/0022-1317-78-10-2419","article-title":"Antigenic structure of the human respiratory syncytial virus G glycoprotein and relevance of hypermutation events for the generation of antigenic variants","volume":"78","author":"Martinez","year":"1997","journal-title":"J Gen Virol"},{"issue":"7","key":"10.1016\/j.vaccine.2016.04.083_bib0635","doi-asserted-by":"crossref","first-page":"5637","DOI":"10.1128\/JVI.73.7.5637-5645.1999","article-title":"Identification of multiple protective epitopes (protectopes) in the central conserved domain of a prototype human respiratory syncytial virus G protein","volume":"73","author":"Plotnicky-Gilquin","year":"1999","journal-title":"J Virol"},{"issue":"10","key":"10.1016\/j.vaccine.2016.04.083_bib0640","doi-asserted-by":"crossref","first-page":"6338","DOI":"10.4049\/jimmunol.0901373","article-title":"Potent high-affinity antibodies for treatment and prophylaxis of respiratory syncytial virus derived from B cells of infected patients","volume":"183","author":"Collarini","year":"2009","journal-title":"J Immunol"},{"issue":"12","key":"10.1016\/j.vaccine.2016.04.083_bib0645","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1005318","article-title":"Respiratory syncytial virus uses CX3CR1 as a receptor on primary human airway epithelial cultures","volume":"11","author":"Johnson","year":"2015","journal-title":"PLOS Pathog"},{"issue":"11","key":"10.1016\/j.vaccine.2016.04.083_bib0650","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.15252\/emmm.201404005","article-title":"Protection and mechanism of action of a novel human respiratory syncytial virus vaccine candidate based on the extracellular domain of small hydrophobic protein","volume":"6","author":"Schepens","year":"2014","journal-title":"EMBO Mol Med"},{"issue":"5","key":"10.1016\/j.vaccine.2016.04.083_bib0655","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/S0022-3476(81)80829-3","article-title":"Risk of respiratory syncytial virus infection for infants from low-income families in relationship to age, sex, ethnic group, and maternal antibody level","volume":"98","author":"Glezen","year":"1981","journal-title":"J Pediatr"},{"issue":"3","key":"10.1016\/j.vaccine.2016.04.083_bib0660","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1128\/JVI.55.3.517-520.1985","article-title":"Quantitative aspects of passive immunity to respiratory syncytial virus infection in infant cotton rats","volume":"55","author":"Prince","year":"1985","journal-title":"J Virol"},{"issue":"4","key":"10.1016\/j.vaccine.2016.04.083_bib0665","first-page":"463","article-title":"Respiratory syncytial virus (RSV) infection in preterm infants and the protective effects of RSV immune globulin (RSVIG). Respiratory Syncytial Virus Immune Globulin Study Group","volume":"95","author":"Groothuis","year":"1995","journal-title":"Pediatrics"},{"issue":"3 Pt 1","key":"10.1016\/j.vaccine.2016.04.083_bib0670","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1542\/peds.102.3.531","article-title":"Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants","volume":"102","author":"The IMpact-RSV Study Group","year":"1998","journal-title":"Pediatrics"},{"issue":"12","key":"10.1016\/j.vaccine.2016.04.083_bib0675","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1016\/S1473-3099(15)00247-9","article-title":"Efficacy of motavizumab for the prevention of respiratory syncytial virus disease in healthy Native American infants: a phase 3 randomised double-blind placebo-controlled trial","volume":"15","author":"O\u2019Brien","year":"2015","journal-title":"Lancet Infect Dis"},{"issue":"2","key":"10.1016\/j.vaccine.2016.04.083_bib0680","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1086\/421524","article-title":"Humoral and mucosal immunity in protection from natural respiratory syncytial virus infection in adults","volume":"190","author":"Walsh","year":"2004","journal-title":"J Infect Dis"},{"issue":"9","key":"10.1016\/j.vaccine.2016.04.083_bib0685","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1164\/rccm.201412-2256OC","article-title":"Impaired antibody-mediated protection and defective IgA B-cell memory in experimental infection of adults with respiratory syncytial virus","volume":"191","author":"Habibi","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"10.1016\/j.vaccine.2016.04.083_bib0690","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1093\/infdis\/163.4.693","article-title":"Immunity to and frequency of reinfection with respiratory syncytial virus","volume":"163","author":"Hall","year":"1991","journal-title":"J Infect Dis"},{"issue":"5","key":"10.1016\/j.vaccine.2016.04.083_bib0695","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1086\/315859","article-title":"Evaluation of a live, cold-passaged, temperature-sensitive, respiratory syncytial virus vaccine candidate in infancy","volume":"182","author":"Wright","year":"2000","journal-title":"J Infect Dis"},{"issue":"8","key":"10.1016\/j.vaccine.2016.04.083_bib0700","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1086\/512615","article-title":"Severe human lower respiratory tract illness caused by respiratory syncytial virus and influenza virus is characterized by the absence of pulmonary cytotoxic lymphocyte responses","volume":"195","author":"Welliver","year":"2007","journal-title":"J Infect Dis"},{"issue":"3A","key":"10.1016\/j.vaccine.2016.04.083_bib0705","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0002-9343(97)80008-3","article-title":"Community respiratory viruses: organ transplant recipients","volume":"102","author":"Wendt","year":"1997","journal-title":"Am J Med"},{"issue":"3","key":"10.1016\/j.vaccine.2016.04.083_bib0710","doi-asserted-by":"crossref","first-page":"203","DOI":"10.7326\/0003-4819-109-3-203","article-title":"Respiratory syncytial virus infection in immunocompromised adults","volume":"109","author":"Englund","year":"1988","journal-title":"Ann Intern Med"},{"issue":"2","key":"10.1016\/j.vaccine.2016.04.083_bib0715","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1056\/NEJM198607103150201","article-title":"Respiratory syncytial viral infection in children with compromised immune function","volume":"315","author":"Hall","year":"1986","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.vaccine.2016.04.083_bib0720","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1097\/00006454-199309000-00006","article-title":"Respiratory syncytial virus illnesses in human immunodeficiency virus- and noninfected children","volume":"12","author":"King","year":"1993","journal-title":"Pediatr Infect Dis J"},{"issue":"3","key":"10.1016\/j.vaccine.2016.04.083_bib0725","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1172\/JCI115362","article-title":"Role of T lymphocyte subsets in the pathogenesis of primary infection and rechallenge with respiratory syncytial virus in mice","volume":"88","author":"Graham","year":"1991","journal-title":"J Clin Investig"},{"key":"10.1016\/j.vaccine.2016.04.083_bib0730","doi-asserted-by":"crossref","first-page":"10224","DOI":"10.1038\/ncomms10224","article-title":"RSV-specific airway resident memory CD8+ T cells and differential disease severity after experimental human infection","volume":"6","author":"Jozwik","year":"2015","journal-title":"Nat Commun"},{"issue":"2","key":"10.1016\/j.vaccine.2016.04.083_bib0735","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1177\/153537020222700208","article-title":"An aged mouse model for RSV infection and diminished CD8(+) CTL responses","volume":"227","author":"Zhang","year":"2002","journal-title":"Exp Biol Med (Maywood)"},{"key":"10.1016\/j.vaccine.2016.04.083_bib0740","first-page":"211","article-title":"Consequences of immature and senescent immune responses for infection with respiratory syncytial virus","volume":"372","author":"Malloy","year":"2013","journal-title":"Curr Top Microbiol Immunol"},{"issue":"4","key":"10.1016\/j.vaccine.2016.04.083_bib0745","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1093\/oxfordjournals.aje.a120957","article-title":"Field evaluation of a respiratory syncytial virus vaccine and a trivalent parainfluenza virus vaccine in a pediatric population","volume":"89","author":"Chin","year":"1969","journal-title":"Am J Epidemiol"},{"issue":"4","key":"10.1016\/j.vaccine.2016.04.083_bib0750","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1093\/oxfordjournals.aje.a120956","article-title":"Respiratory virus immunization. I. A field trial of two inactivated respiratory virus vaccines; an aqueous trivalent parainfluenza virus vaccine and an alum-precipitated respiratory syncytial virus vaccine","volume":"89","author":"Fulginiti","year":"1969","journal-title":"Am J Epidemiol"},{"issue":"4","key":"10.1016\/j.vaccine.2016.04.083_bib0755","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1093\/oxfordjournals.aje.a120954","article-title":"An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine","volume":"89","author":"Kapikian","year":"1969","journal-title":"Am J Epidemiol"},{"issue":"4","key":"10.1016\/j.vaccine.2016.04.083_bib0760","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1093\/oxfordjournals.aje.a120955","article-title":"Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine","volume":"89","author":"Kim","year":"1969","journal-title":"Am J Epidemiol"},{"issue":"1","key":"10.1016\/j.vaccine.2016.04.083_bib0765","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1203\/PDR.0b013e3180686ce0","article-title":"Atypical measles and enhanced respiratory syncytial virus disease (ERD) made simple","volume":"62","author":"Polack","year":"2007","journal-title":"Pediatr Res"},{"key":"10.1016\/j.vaccine.2016.04.083_bib0770","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.coi.2015.04.005","article-title":"Novel antigens for RSV vaccines","volume":"35","author":"Graham","year":"2015","journal-title":"Curr Opin Immunol"},{"issue":"22","key":"10.1016\/j.vaccine.2016.04.083_bib0775","doi-asserted-by":"crossref","first-page":"11561","DOI":"10.1128\/JVI.76.22.11561-11569.2002","article-title":"Immunization of macaques with formalin-inactivated respiratory syncytial virus (RSV) induces interleukin-13-associated hypersensitivity to subsequent RSV infection","volume":"76","author":"De Swart","year":"2002","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2016.04.083_bib0780","first-page":"327","article-title":"Bovine model of respiratory syncytial virus infection","volume":"372","author":"Taylor","year":"2013","journal-title":"Curr Top Microbiol Immunol"},{"key":"10.1016\/j.vaccine.2016.04.083_bib0785","doi-asserted-by":"crossref","first-page":"40","DOI":"10.4172\/jaa.1000093","article-title":"Modeling Human Respiratory Viral Infections in the Cotton Rat","volume":"6","author":"Blanco","year":"2014","journal-title":"J Antivir Antiretrovir"},{"issue":"4","key":"10.1016\/j.vaccine.2016.04.083_bib0790","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.4049\/jimmunol.151.4.2032","article-title":"Priming immunization determines T helper cytokine mRNA expression patterns in lungs of mice challenged with respiratory syncytial virus","volume":"151","author":"Graham","year":"1993","journal-title":"J Immunol"},{"issue":"2","key":"10.1016\/j.vaccine.2016.04.083_bib0795","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1128\/JCM.24.2.197-202.1986","article-title":"Dissociation between serum neutralizing and glycoprotein antibody responses of infants and children who received inactivated respiratory syncytial virus vaccine","volume":"24","author":"Murphy","year":"1986","journal-title":"J Clin Microbiol"},{"issue":"8","key":"10.1016\/j.vaccine.2016.04.083_bib0800","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1128\/JCM.26.8.1595-1597.1988","article-title":"Formalin-inactivated respiratory syncytial virus vaccine induces antibodies to the fusion glycoprotein that are deficient in fusion-inhibiting activity","volume":"26","author":"Murphy","year":"1988","journal-title":"J Clin Microbiol"},{"issue":"6","key":"10.1016\/j.vaccine.2016.04.083_bib0805","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1084\/jem.20020781","article-title":"A role for immune complexes in enhanced respiratory syncytial virus disease","volume":"196","author":"Polack","year":"2002","journal-title":"J Exp Med"},{"issue":"12","key":"10.1016\/j.vaccine.2016.04.083_bib0810","doi-asserted-by":"crossref","first-page":"7444","DOI":"10.1128\/JVI.66.12.7444-7451.1992","article-title":"Pulmonary histopathology induced by respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV-immunized BALB\/c mice is abrogated by depletion of CD4+ T cells","volume":"66","author":"Connors","year":"1992","journal-title":"J Virol"},{"issue":"7","key":"10.1016\/j.vaccine.2016.04.083_bib0815","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/0264-410X(92)90397-3","article-title":"Cotton rats previously immunized with a chimeric RSV FG glycoprotein develop enhanced pulmonary pathology when infected with RSV, a phenomenon not encountered following immunization with vaccinia \u2013 RSV recombinants or RSV","volume":"10","author":"Connors","year":"1992","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2016.04.083_bib0820","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1086\/338009","article-title":"Altered synthesis of interleukin-12 and type 1 and type 2 cytokinesin rhesus macaques during measles and atypical measles","volume":"185","author":"Polack","year":"2002","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2016.04.083_bib0825","first-page":"259","article-title":"Live-attenuated respiratory syncytial virus vaccines","volume":"372","author":"Karron","year":"2013","journal-title":"Curr Top Microbiol Immunol"},{"issue":"312","key":"10.1016\/j.vaccine.2016.04.083_bib0830","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aac8463","article-title":"A gene deletion that up-regulates viral gene expression yields an attenuated RSV vaccine with improved antibody responses in children","volume":"7","author":"Karron","year":"2015","journal-title":"Sci Transl Med"},{"issue":"18","key":"10.1016\/j.vaccine.2016.04.083_bib0835","doi-asserted-by":"crossref","first-page":"9499","DOI":"10.1128\/JVI.01373-15","article-title":"Enhanced neutralizing antibody response induced by respiratory syncytial virus prefusion F protein expressed by a vaccine candidate","volume":"89","author":"Liang","year":"2015","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2016.04.083_bib0840","first-page":"1","article-title":"Sendai virus as a backbone for vaccines against RSV and other human paramyxoviruses","author":"Russell","year":"2015","journal-title":"Expert Rev Vaccines"},{"issue":"3","key":"10.1016\/j.vaccine.2016.04.083_bib0845","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1093\/infdis\/145.3.311","article-title":"Parenteral administration of live respiratory syncytial virus vaccine: results of a field trial","volume":"145","author":"Belshe","year":"1982","journal-title":"J Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2016.04.083_bib0850","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1038\/mt.2013.142","article-title":"Genetic vaccine for respiratory syncytial virus provides protection without disease potentiation","volume":"22","author":"Johnson","year":"2014","journal-title":"Mol Ther"},{"issue":"300","key":"10.1016\/j.vaccine.2016.04.083_bib0855","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aac5757","article-title":"Efficacy of a virus-vectored vaccine against human and bovine respiratory syncytial virus infections","volume":"7","author":"Taylor","year":"2015","journal-title":"Sci Transl Med"},{"issue":"36","key":"10.1016\/j.vaccine.2016.04.083_bib0860","doi-asserted-by":"crossref","first-page":"14604","DOI":"10.1073\/pnas.1209367109","article-title":"Nonviral delivery of self-amplifying RNA vaccines","volume":"109","author":"Geall","year":"2012","journal-title":"Proc Natl Acad Sci USA"},{"issue":"24","key":"10.1016\/j.vaccine.2016.04.083_bib0865","doi-asserted-by":"crossref","first-page":"13466","DOI":"10.1128\/JVI.01741-13","article-title":"Respiratory syncytial virus G protein CX3C motif impairs human airway epithelial and immune cell responses","volume":"87","author":"Chirkova","year":"2013","journal-title":"J Virol"},{"issue":"3","key":"10.1016\/j.vaccine.2016.04.083_bib0870","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1128\/JVI.06096-11","article-title":"Respiratory syncytial virus glycoprotein G interacts with DC-SIGN and L-SIGN to activate ERK1 and ERK2","volume":"86","author":"Johnson","year":"2012","journal-title":"J Virol"},{"issue":"2","key":"10.1016\/j.vaccine.2016.04.083_bib0875","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1128\/JVI.01709-09","article-title":"Newcastle disease virus-like particles containing respiratory syncytial virus G protein induced protection in BALB\/c mice, with no evidence of immunopathology","volume":"84","author":"Murawski","year":"2010","journal-title":"J Virol"},{"issue":"17","key":"10.1016\/j.vaccine.2016.04.083_bib0880","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1016\/j.vaccine.2013.02.043","article-title":"Efficacy and safety of an intranasal virosomal respiratory syncytial virus vaccine adjuvanted with monophosphoryl lipid A in mice and cotton rats","volume":"31","author":"Kamphuis","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.04.083_bib0885","doi-asserted-by":"crossref","first-page":"282","DOI":"10.3389\/fimmu.2013.00282","article-title":"Bacterium-like particles for efficient immune stimulation of existing vaccines and new subunit vaccines in mucosal applications","volume":"4","author":"Van Braeckel-Budimir","year":"2013","journal-title":"Front Immunol"},{"issue":"6165","key":"10.1016\/j.vaccine.2016.04.083_bib0890","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1126\/science.342.6165.1442-a","article-title":"In vaccine design, looks do matter","volume":"342","author":"2013 Runners-Up","year":"2013","journal-title":"Science"},{"issue":"6158","key":"10.1016\/j.vaccine.2016.04.083_bib0895","first-page":"546","article-title":"Vaccines. Structural biology triumph offers hope against a childhood killer","volume":"342","author":"Cohen","year":"2013","journal-title":"Science"},{"issue":"27","key":"10.1016\/j.vaccine.2016.04.083_bib0900","doi-asserted-by":"crossref","first-page":"11133","DOI":"10.1073\/pnas.1309070110","article-title":"Architecture of respiratory syncytial virus revealed by electron cryotomography","volume":"110","author":"Liljeroos","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"issue":"13","key":"10.1016\/j.vaccine.2016.04.083_bib0905","doi-asserted-by":"crossref","first-page":"7602","DOI":"10.1128\/JVI.00256-14","article-title":"Structural analysis of respiratory syncytial virus reveals the position of M2-1 between the matrix protein and the ribonucleoprotein complex","volume":"88","author":"Kiss","year":"2014","journal-title":"J Virol"},{"issue":"7467","key":"10.1016\/j.vaccine.2016.04.083_bib0910","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1038\/nature12442","article-title":"Cross-neutralization of four paramyxoviruses by a human monoclonal antibody","volume":"501","author":"Corti","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2016.04.083_bib0915","doi-asserted-by":"crossref","first-page":"8143","DOI":"10.1038\/ncomms9143","article-title":"A highly stable prefusion RSV F vaccine derived from structural analysis of the fusion mechanism","volume":"6","author":"Krarup","year":"2015","journal-title":"Nat Commun"},{"issue":"6158","key":"10.1016\/j.vaccine.2016.04.083_bib0920","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1126\/science.1243283","article-title":"Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus","volume":"342","author":"McLellan","year":"2013","journal-title":"Science"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X16302572?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X16302572?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,8,18]],"date-time":"2023-08-18T06:14:52Z","timestamp":1692339292000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X16302572"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6]]},"references-count":92,"journal-issue":{"issue":"30","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["S0264410X16302572"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2016.04.083","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2016,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Vaccines against respiratory syncytial virus: The time has finally come","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2016.04.083","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}